Welcome to our dedicated page for Icecure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial costs, FDA milestones buried in R&D tables, and cash-burn details all hide inside IceCure Medical’s (ICCM) SEC reports—and some filings top 200 pages. For anyone tracking the company’s liquid-nitrogen cryoablation platform, overlooking a single line about a pivotal study or financing tranche can upend an investment thesis overnight.
Stock Titan’s AI fixes that by converting every new EDGAR submission into a concise, plain-English brief. Need the IceCure Medical quarterly earnings report 10-Q filing or the latest IceCure Medical insider trading Form 4 transactions before the bell? Our engine tags ProSense revenue, clinical-trial spending, and regulatory timelines instantly. Real-time alerts on IceCure Medical Form 4 insider transactions real-time show how executives act when key data readouts approach.
Navigate faster with:
- 10-K annual report—our tool delivers an IceCure Medical annual report 10-K simplified, highlighting cash runway, patent life, and cryotherapy market share.
- 8-K material events—get IceCure Medical 8-K material events explained, from FDA clearances to strategic partnerships.
- Proxy statements—review IceCure Medical proxy statement executive compensation to gauge incentive alignment.
- Form 4—track IceCure Medical executive stock transactions Form 4 and spot buying or selling patterns with ease.
Common questions like “How do I read IceCure’s 10-K?” or “What does this 8-K mean for upcoming trials?” are answered right on the document page, ensuring you’re understanding IceCure Medical SEC documents with AI instead of deciphering legal jargon.
From IceCure Medical earnings report filing analysis to pipeline risk assessment, every disclosure is indexed, summarized, and updated the moment it hits EDGAR—so you make decisions backed by complete, current information.
IceCure Medical Ltd. reported that it issued a press release announcing that its ProSense® cryoablation system received regulatory approval in Switzerland for use in treating breast, lung, liver, and kidney cancer. The press release, dated November 18, 2025, is furnished as an exhibit to this report. Most of the press release (excluding its second paragraph) is also incorporated by reference into IceCure’s existing shelf and employee equity compensation registration statements on Forms F-3 and S-8, making the Swiss approval disclosure part of those offering documents.
IceCure Medical Ltd. (ICCM) furnished a Form 6-K noting it issued a press release titled “IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification.” The press release is attached as Exhibit 99.1.
The submission states this report is incorporated by reference into the company’s existing registration statements on Form F-3 (Nos. 333-258660, 333-267272, 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620, 333-281587).
IceCure Medical Ltd. (ICCM) announced a management change. On November 5, 2025, the Board promoted Mr. Shay Levav, previously Vice President of Regulatory and Quality Assurance and Clinical Applications since September 2020, to Chief Operating Officer.
The company also furnished a press release on November 10, 2025, and incorporated it by reference into its existing Form F-3 and Form S-8 registration statements.
IceCure Medical (ICCM) furnished a Form 6-K announcing it issued a press release titled “IceCure’s Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival.”
The press release (Exhibit 99.1) is incorporated by reference into the Company’s Registration Statements on Form F-3 (Nos. 333-258660, 333-267272, 333-290046) and Form S-8 (Nos. 333-270982, 333-264578, 333-262620, 333-281587).
IceCure Medical reported an executive change, delivering a notice of termination to Vice President of Operations and Services Galit Malik, with her employment ending on January 15, 2026. The company stated the termination was not related to any disagreement regarding operations, policies, or practices.
The report is furnished on Form 6-K and is incorporated by reference into IceCure Medical’s existing Form F-3 and Form S-8 registration statements.
FAQ
What is the current stock price of Icecure Medical Ltd. (ICCM)?
What is the market cap of Icecure Medical Ltd. (ICCM)?
